NASDAQ:CDXS - Codexis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$18.30 +0.35 (+1.95 %)
(As of 09/21/2018 09:21 AM ET)
Previous Close$17.95
Today's Range$17.85 - $18.35
52-Week Range$5.63 - $19.30
Volume276,431 shs
Average Volume343,597 shs
Market Capitalization$960.55 million
P/E Ratio-36.60
Dividend YieldN/A
Beta-2.07
Codexis logoCodexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

Receive CDXS News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Industrial organic chemicals
Sub-IndustryBiotechnology
SectorIndustrial Products
SymbolNASDAQ:CDXS
CUSIP19200510
Phone650-421-8100

Debt

Debt-to-Equity RatioN/A
Current Ratio4.04
Quick Ratio3.98

Price-To-Earnings

Trailing P/E Ratio-36.60
Forward P/E Ratio-91.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$50.02 million
Price / Sales19.58
Cash FlowN/A
Price / CashN/A
Book Value$0.51 per share
Price / Book35.88

Profitability

EPS (Most Recent Fiscal Year)($0.50)
Net Income$-22,990,000.00
Net Margins-29.83%
Return on Equity-61.93%
Return on Assets-32.42%

Miscellaneous

Employees116
Outstanding Shares53,510,000
Market Cap$960.55 million

Codexis (NASDAQ:CDXS) Frequently Asked Questions

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings data on Wednesday, August, 8th. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. The biotechnology company had revenue of $13.54 million for the quarter, compared to analysts' expectations of $11.87 million. Codexis had a negative return on equity of 61.93% and a negative net margin of 29.83%. View Codexis' Earnings History.

When is Codexis' next earnings date?

Codexis is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Codexis.

What price target have analysts set for CDXS?

5 analysts have issued 1 year target prices for Codexis' stock. Their predictions range from $11.00 to $20.00. On average, they expect Codexis' stock price to reach $15.40 in the next twelve months. This suggests that the stock has a possible downside of 15.8%. View Analyst Price Targets for Codexis.

What is the consensus analysts' recommendation for Codexis?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Codexis.

Who are some of Codexis' key competitors?

Who are Codexis' key executives?

Codexis' management team includes the folowing people:
  • Mr. John J. Nicols, Pres, CEO & Director (Age 54)
  • Mr. Gordon T. B. Sangster, Sr. VP & CFO (Age 65)
  • Dr. James J. Lalonde, Sr. VP of R&D (Age 57)
  • Mr. Achilles Antonio Clement, Director of Latin America
  • Ms. Shawn Clairmont, Sr. Director of Molecular Diagnostics

Has Codexis been receiving favorable news coverage?

News stories about CDXS stock have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Codexis earned a coverage optimism score of 0.18 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Codexis.

Who are Codexis' major shareholders?

Codexis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.39%), Baillie Gifford & Co. (4.97%), Opaleye Management Inc. (3.27%), Wells Fargo & Company MN (2.53%), Prescott Group Capital Management L.L.C. (2.22%) and First Light Asset Management LLC (1.57%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Michael D Aldridge, Pam P Cheng, Patrick Y Yang, Thomas R Baruch and Ventures Vii Affiliates F Vivo. View Institutional Ownership Trends for Codexis.

Which major investors are selling Codexis stock?

CDXS stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Cortina Asset Management LLC, Prescott Group Capital Management L.L.C., Comprehensive Portfolio Management LLC, EAM Investors LLC and Bradley Foster & Sargent Inc. CT. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Michael D Aldridge, Pam P Cheng, Patrick Y Yang and Thomas R Baruch. View Insider Buying and Selling for Codexis.

Which major investors are buying Codexis stock?

CDXS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Castleark Management LLC, Baillie Gifford & Co., First Light Asset Management LLC, Wells Fargo & Company MN, Northern Trust Corp and Alambic Investment Management L.P.. View Insider Buying and Selling for Codexis.

How do I buy shares of Codexis?

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $18.30.

How big of a company is Codexis?

Codexis has a market capitalization of $960.55 million and generates $50.02 million in revenue each year. The biotechnology company earns $-22,990,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Codexis employs 116 workers across the globe.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at ir[email protected]


MarketBeat Community Rating for Codexis (NASDAQ CDXS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  430
MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. Vote "Outperform" if you believe CDXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel